

5-Year Efficacy and Safety of iTrack™ to be Spotlighted at ESCRS 2021

Adelaide, Australia, 7 October 2021 – Nova Eye Medical Limited (ASX: EYE)(Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces the results of a retrospective case series which demonstrating the efficacy and safety of canaloplasty using the Company’s proprietary iTrack™ canaloplasty microcatheter over a 60-month follow-up period. The retrospective case series data will be presented at the 39th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) from October 8-11, 2021.

In the retrospective case series, Prof. Koerber and Dr. Ondrejka evaluated the long-term effectiveness of iTrack™ canaloplasty in reducing intraocular pressure (IOP) and glaucoma medications in patients with uncontrolled or controlled open-angle glaucoma (OAG). Most eyes, 23 out of 27, were treated with canaloplasty combined with cataract surgery and 4 eyes were treated with canaloplasty as a standalone procedure.

Prof. Koerber concluded that, based on the results of this 60-month study, iTrack™ canaloplasty achieves a significant reduction in IOP as compared to baseline, along with a decrease in medication burden. The results also showed that performing canaloplasty with the iTrack™ is a safe procedure associated with a low risk of complications.

Commenting on the iTrack™ data to be presented at ESCRS 2021, Managing Director of Nova Eye Medical, Tom Spurling, “This recent work by Prof. Koerber and Dr. Ondrejka demonstrates the significant utility of canaloplasty in delaying the need for more invasive surgical intervention for up to 60 months.”

iTrack™ canaloplasty performed as a standalone procedure or in conjunction with cataract surgery was found to be an effective option for maintaining a sustained IOP reduction in patients with OAG up to 5 years from 19.8 ± 5.2 (n=27) at baseline to 15.0 ± 2.6 (n=26), 15.6 ± 3.3 (n=25), 14.7 ± 3.8 (n=21), 14.6 ± 3.0 (n=18) and 14.4 ± 3.3 (n=14) at 12, 24, 36, 48 and 60 months respectively. iTrack™ canaloplasty was also effective in reducing glaucoma medication dependence, with the mean number of medications falling from 1.93 at baseline to 1.21 at 60-months and 57% of eyes on 1 medication or less at 60-months.

In the retrospective case series, no severe complications occurred either intraoperatively or postoperatively.

Prof. Koerber’s ESCRS iTrack™ abstract can be accessed via the ESCRS website:

<https://congress.escrs.org/wp-content/uploads/2021/09/ESCRS-2021-Free-Paper-Cataract.pdf>

(Refer to page 78)

This release dated 7 October 2021 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

– ENDS –

Company

Tom Spurling
Managing Director
Nova Eye Medical Limited
W +61 417 818 658
tspurling@nova-eye.com

Investors

Dr. Tom Duthy
Investor Relations & Corporate Development
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com

Media

Kate Hunt
Head of Marketing
Nova Eye Medical Limited
W +61 404 080 679
khunt@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com